Early DMD diagnosis and new treatments extend life expectancy by decades

Life expectancy for people with Duchenne muscular dystrophy (DMD) has risen steadily in recent decades. Advances in treatment and better management of related conditions have played a key role. New research now shows how early diagnosis and targeted care are improving outcomes for patients worldwide.

In the past, children with DMD were often diagnosed between 2.5 and 3 years old. Today, that average has dropped to 1.5–2 years, thanks to neonatal screening programmes and greater awareness. Countries like Japan, where screening is widespread, frequently diagnose infants under one year old. Meanwhile, regions without such programmes—including parts of Europe, the US, and especially Latin America and Africa—still see delays, with diagnoses often occurring at 2–3 years or later.

Early detection allows for faster treatment, which can slow the disease's progression. Access to corticosteroids, gene therapy, and other medications has further extended survival rates. A 2021 review found that those born after 1990 had a median life expectancy of 28.1 years, compared to just 18.3 years for patients born before 1970. Better care for co-occurring conditions also makes a difference. Heart-protective drugs and treatment for breathing difficulties reduce pneumonia-related deaths. Patients using ventilators now have a median life expectancy of 29.9 to 31.8 years, according to a 2020 study. However, low body weight and severe breathing problems linked to cardiomyopathy can still shorten survival.

The combination of earlier diagnosis, improved treatments, and proactive management has transformed life expectancy for DMD patients. While challenges remain, ongoing research and better access to care continue to extend and enhance quality of life for those affected by the disease.